REG - Proteome Sciences - AGM Statement

Proteome SciencesAnnouncement

16/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240516:nRSP6166Oa&default-theme=true

RNS Number : 6166O  Proteome Sciences PLC  16 May 2024

16 May 2024

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting Statement

 

At the Company's Annual General Meeting ("AGM") being held today at 12.00
noon, the Chairman, Christopher Pearce, will make the following statement:

 

Since the start of 2024, we have seen significant customer engagement and
interest in proteomics services reflected by the considerable increase in
customer contact and quotations provided, including the substantial contract
win from a US biopharmaceutical company announced on 26 April 2024.

 

The Company is confident and well positioned to see the business return to
growth in 2024, following the launch of single cell proteomics ("SCP"), the
introduction of new next generation tags in the isobaric and isotopic field,
and the opening of the new facility in the USA during 2023 to provide services
locally.

 

For further information:

 Proteome Sciences plc
 Dr. Mariola Soehngen, Chief Executive Officer                           Tel: +44 (0)20 7043 2116

 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 Abdelghani Omari, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Lauren Wright (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMAAMFTMTJBBFI